Summary
The AI claims provided are largely about pricing/availability and comparator antiemetic drugs rather than the FDA-approved prescribing information for ondansetron ODT. The only on-label medical claim (indication for prevention of nausea/vomiting with chemo/radiation/surgery) is partially aligned with Section 1, but contraindications, warnings/precautions, dosage/administration, and safety details are not evaluated or matched. Because most claims are not supported by (or relevant to) the provided FDA label excerpts, overall alignment is poor.
Category Scores
Accurate Statements
Ondansetron is used to prevent nausea and vomiting often associated with chemotherapy, radiation therapy, or surgery.
Supported in Section 1 (prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, moderately emetogenic cancer chemotherapy, radiotherapy, and postoperative nausea and/or vomiting).
Ondansetron orally disintegrating tablets correspond to ondansetron use for prevention of nausea/vomiting associated with chemotherapy, radiotherapy, and postoperative nausea/vomiting (implied by the above claim).
Section 1.
Unsupported Statements
Ondansetron is generally available in 4 mg and 8 mg strengths.
Not supported by the provided FDA label excerpts.
For a prescription of 30 pills of ondansetron 4 mg, the cost can range from approximately $10 to $40.
Pricing/cost ranges are not addressed in the provided FDA label excerpts.
The price for ondansetron 8 mg tablets typically falls within a similar range, or slightly higher.
Not supported by provided FDA label excerpts.
Without insurance, prices for the same quantity of ondansetron can potentially exceed $50.
Not supported by provided FDA label excerpts.
Generic ondansetron is widely available.
Availability is not addressed in the provided FDA label excerpts.
Generic ondansetron helps keep costs down compared to brand-name alternatives.
Cost comparison is not addressed in provided FDA label excerpts.
Prescription drug plans often reduce out-of-pocket expenses for ondansetron.
Not addressed in provided FDA label excerpts.
The specific copay or coinsurance depends on an individual's insurance policy.
Not addressed in provided FDA label excerpts.
Prices for ondansetron can differ between national pharmacy chains, independent pharmacies, and online prescription drug services.
Not addressed in provided FDA label excerpts.
Manufacturers of ondansetron may have slight price variations between different generic manufacturers.
Not addressed in provided FDA label excerpts.
Ondansetron is also available in other forms such as orally disintegrating tablets or injections, which may have different cost structures.
Formulations/cost structures are not addressed in provided FDA label excerpts.
Choosing generic ondansetron is significantly less expensive than any brand-name versions that may still exist.
Not addressed in provided FDA label excerpts.
Discount cards or coupons can lower prescription costs for ondansetron, even for those with insurance.
Not addressed in provided FDA label excerpts.
Prescription discount programs are widely available.
Not addressed in provided FDA label excerpts.
Reputable online pharmacies can sometimes offer lower prices due to reduced overhead.
Not addressed in provided FDA label excerpts.
Reputable online pharmacies require a valid prescription.
Not addressed in provided FDA label excerpts.
Purchasing a larger supply of ondansetron, if medically appropriate and prescribed, can sometimes result in a lower per-pill cost.
Not addressed in provided FDA label excerpts.
Granisetron is similar in function to ondansetron.
Not addressed in provided FDA label excerpts for ondansetron ODT.
Granisetron is available in generic form.
Not addressed in provided FDA label excerpts.
Granisetron cost can be comparable or slightly higher than ondansetron, depending on formulation and dosage.
Not addressed in provided FDA label excerpts.
Palonosetron is a more potent and longer-acting 5-HT3 receptor antagonist.
Not addressed in provided FDA label excerpts.
Palonosetron is generally more expensive than ondansetron, particularly for brand-name versions.
Not addressed in provided FDA label excerpts.
Generic palonosetron options are emerging.
Not addressed in provided FDA label excerpts.
Metoclopramide is used for nausea and vomiting.
Not addressed in provided FDA label excerpts.
Metoclopramide is a less expensive generic option.
Not addressed in provided FDA label excerpts.
Metoclopramide may have a different efficacy profile than ondansetron.
Not addressed in provided FDA label excerpts.
Metoclopramide may have more side effects than ondansetron.
Not addressed in provided FDA label excerpts.
Dexamethasone is often used in combination with other antiemetics.
Not addressed in provided FDA label excerpts.
Dexamethasone can help manage chemotherapy-induced nausea and vomiting.
Not addressed in provided FDA label excerpts.
Dexamethasone is generally affordable.
Not addressed in provided FDA label excerpts.
Contradictions
Important Omissions
If the AI response included dosing/administration recommendations, these were not provided and thus cannot be checked against the label’s recommended dose regimens and timing (e.g., postoperative 16 mg 1 hour before induction; chemo/radiotherapy regimens; hepatic impairment maximum).
Importance:
Moderate
Contraindications and key warnings/precautions (e.g., apomorphine contraindication; hypersensitivity; QT prolongation/avoid in congenital long QT; serotonin syndrome; ileus/gastric distension masking) were not mentioned, so safety-relevant label content is omitted from the AI claims set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only on-label medical claim present is consistent with Section 1. However, most claims are unrelated to ondansetron prescribing information and there is no label-based dosing or safety context provided, so completeness relative to the label is poor, though no direct label conflict is identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Major Revision
Primary Issue
Most claims are about pricing/availability and comparators and are not supported by the provided FDA prescribing information excerpts; no label-consistent dosing/administration or safety details are evaluated or included.
Suggested Improvement
Limit medical statements to what is supported in ondansetron ODT Section 1 (indications) and align any dosing/administration or safety discussion with Sections 2, 4, 5, and 7 of the FDA label excerpts provided.